Elagolix is a selective, orally active GnRH receptor antagonist (Ki = 0.9 nM) that inhibits GnRH-induced signaling (IC50 = 1.5 nM). It suppresses luteinizing hormone production in vivo and has been used in formulations for treating endometriosis-related pain. Elagolix is highly selective, with minimal activity against CYP3A4 and other receptors. Reagent grade, for research purpose.
Usually ships within 24 hours.